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Aims To compare primary percutaneous coronary intervention (pPCI) and ﬁbrinolysis in very old patients with ST-segment
elevation myocardial infarction (STEMI), in whom head-to-head comparisons between both strategies are scarce.
Methods
and results
Patients ≥75 years old with STEMI ,6 h were randomized to pPCI or ﬁbrinolysis. The primary endpoint was a com-
posite of all-cause mortality, re-infarction, or disabling stroke at 30 days. The trial was prematurely stopped due to
slow recruitment after enroling 266 patients (134 allocated to pPCI and 132 to ﬁbrinolysis). Both groups were well
balanced in baseline characteristics. Mean age was 81 years. The primary endpoint was reached in 25 patients in the
pPCI group (18.9%) and 34 (25.4%) in the ﬁbrinolysis arm [odds ratio (OR), 0.69; 95% conﬁdence interval (CI) 0.38–
1.23; P ¼ 0.21]. Similarly, non-signiﬁcant reductions were found in death (13.6 vs. 17.2%, P ¼ 0.43), re-infarction (5.3
vs. 8.2%, P ¼ 0.35), or disabling stroke (0.8 vs. 3.0%, P ¼ 0.18). Recurrent ischaemia was less common in pPCI-treated
patients (0.8 vs. 9.7%, P , 0.001). No differences were found in major bleeds. A pooled analysis with the two pre-
vious reperfusion trials performed in older patients showed an advantage of pPCI over ﬁbrinolysis in reducing death,
re-infarction, or stroke at 30 days (OR, 0.64; 95% CI 0.45–0.91).
Conclusion Primary PCI seems to be the best reperfusion therapy for STEMI even for the oldest patients. Early contemporary
ﬁbrinolytic therapy may be a safe alternative to pPCI in the elderly when this is not available.
Clinicaltrials.gov # NCT00257309.
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Primary percutaneous coronary intervention (pPCI) is currently
the treatment of choice for patients presenting with ST-segment
elevation myocardial infarction (STEMI). Fibrinolysis is a valuable
alternative when mechanical reperfusion is not available in a
timely fashion. However, the value of these therapies in very old
patients, the fastest growing population group, is not well estab-
lished because elderly patients have been either excluded or
rarely enroled in reperfusion clinical trials.
1–4 In fact, only two
small randomized trials comparing pPCI and ﬁbrinolysis in the
elderly have been performed, with discordant results.
5–7
We undertook the TRIANA (TRatamiento del Infarto Agudo de
miocardio eN Ancianos) trial to compare the efﬁcacy and safety of
pPCI and ﬁbrinolysis in very old STEMI patients. We hypothesized
that mechanical reperfusion was superior to ﬁbrinolysis to reduce
the incidence of death, re-infarction, and disabling stroke at 30 days.
Methods
TRIANA was a randomized multicentre, open-label clinical trial, which
included patients ≥75 years of age presenting with STEMI within the
ﬁrst 6 h after symptom onset at one of the participating centres (23
Spanish hospitals, all of them with cath lab facilities and an active
primary angioplasty programme), who were eligible for ﬁbrinolytic
therapy and capable of providing informed consent prior to randomiz-
ation. ST-segment elevation myocardial infarction was deﬁned by the
presence of chest pain lasting at least 20 min not responding to
nitrates, plus one of the following: ST-segment elevation ≥2m mi n
two or more electrocardiographic precordial leads or ST-elevation
≥1 mm in two or more frontal leads, or left bundle branch block.
Exclusion criteria included any documented contraindication to the
use of ﬁbrinolytics according to the current European Society of Cardi-
ology guidelines,
8 presence of cardiogenic shock at the time of ran-
domization, an estimated door-to-balloon time .120 min; STEMI
suspected as being caused by stent thrombosis, chronic renal failure
(creatinine .2.5 mg/dL), expected life expectancy ,12 months, or par-
ticipation in another clinical trial within 30 days prior to randomization.
The study protocol was approved by all institutional Ethics Committees.
Immediately after STEMI was diagnosed and inclusion/exclusion cri-
teria conﬁrmed, a written informed consent was obtained for each
patient (an oral consent was accepted provided there was written
consent of a witness related to the patient and independent from
the study and enroling institution if the patient was unable to sign it).
Consenting patients were randomized through a central telephone
system, and allocated to the selected strategy.
Fibrinolysis group
Immediately after randomization, a weight-adjusted single intravenous
dose of tenecteplase (TNK) was given ranging from 30 mg in patients
,60 kg to 50 mg in those weighting ≥90 kg. Simultaneously, a
60 units/kg bolus of unfractionated heparin was administered up to a
maximum of 4000 units followed by an infusion of 12 units/kg/h (up
to a maximum of 1000 units/h) with an initial adjustment to maintain
an activated partial thromboplastin time 1.5–2 times the upper
normal limit. Based on the results of the COMMIT trial,
9 clopidogrel
75 mg daily without loading dose was added since January 2007. An
electrocardiogram (ECG) was routinely performed 90 min after lytic
administration, and urgent coronary angiography indicated if there
were no signs of coronary reperfusion. The use of glycoprotein
IIb/IIIa inhibitors was discouraged if rescue PCI was needed. After
reperfusion, the use of coronary angiography was recommended
only when there was evidence of spontaneous or induced recurrent
myocardial ischaemia.
Primary percutaneous coronary
intervention group
Patients were transferred to the cath lab as soon as possible. Both cor-
onary arteries were visualized; left ventriculography was not per-
formed routinely. Coronary angioplasty was performed at the
investigator’s discretion using any approved techniques and devices.
Only the culprit vessel was targeted for pPCI. At the beginning of
the procedure, a bolus of 60 units/kg of unfractionated heparin (with
a maximum of 4000 units) was administered. Patients who received
a stent were treated with clopidogrel, 300 mg loading dose given
immediately before implantation, and 75 mg daily with a variable dur-
ation according to the type of stent. Use of glycoprotein IIb/IIIa
inhibitors was discretionary. Concomitant medication such as aspirin,
b-blockers, angiotensin-converting enzyme-inhibitors, statins, or
others were given according to the guidelines.
The primary endpoint of the study was the incidence of the combi-
nation of all-cause mortality, re-infarction, or disabling stroke at 30 days
after randomization. Secondary endpoints were the incidences of
major bleeding, recurrent ischaemia requiring urgent catheterization, all-
causemortality,andcauseofdeathat30days,andtimeelapseduntilpres-
entation of any component of the composite endpoint at 12 months.
Event adjudication and operational
deﬁnitions
All major events were centrally adjudicated by an independent expert
committee (Appendix 1) blinded to the treatment received by the
patients, using standardized deﬁnitions (Appendix 2).
Statistical analysis
Continuous variables are summarized using medians and 25th–75th
percentiles unless otherwise indicated; discrete variables are rep-
resented as frequencies and percentages. x
2 tests were used for com-
parisons between proportions with calculations of odds ratios (ORs)
Figure 1 Chart ﬂow of management in patients randomized to
the TRIANA study. PCI, percutaneous coronary intervention.
H. Bueno et al. 52and exact 95% conﬁdence intervals (CIs). When the number of
expected cases was less than ﬁve, Fisher ´s exact test was used. The
Student’s t-test or the Mann–Whitney U-test was used to compare
continuous values. Survival curves were calculated by the Kaplan–
Meier product-limit method. Adjusted survival analysis was performed
by ﬁtting Cox proportional hazards models. Because of the small
sample size, this was not used as a multivariate model but enabled
us to calculate hazard ratios, which may be interpreted as risk ratios,
with 95% CIs. All endpoints underwent intention-to-treat analysis
with P-values , 0.05 considered signiﬁcant.
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Table 2 Reperfusion-related variables
Primary PCI
(n 5 132)
Fibrinolysis
(n 5 134)
P-value
Times, minutes (median, 25th–75th percentiles)
Symptom onset to
randomization
180 (135–255) 180 (135–263) 0.991
Symptom onset to
balloon or needle
245 (191–310) 195 (150–270) ,0.0001
Randomization to
balloon or needle
59 (35–75) 10 (5–15) ,0.0001
Door-to-balloon or
needle
99 (73–133) 52 (32–69) 0.002
Start of reperfusion
≤120 min, n (%)
5 (3.8) 18 (13.4) ,0.0001
Fibrinolysis, n (%) 1 (0.8) 129 (96.3)
Tenecteplase dose
(mg, mean+SD)
—3 7 + 5
Effective
reperfusion, n (%)
— 99 (73.9)
Rescue PCI, n (%) — 20 (14.9)
Primary PCI, n (%) 130 (98.5) 3 (2.2)
Baseline results
Infarct-related
artery, n (%)
Left main 1 (0.8) —
Left anterior
descending
56 (42.4) —
Circumﬂex 18 (13.6) —
Right coronary 49 (37.1) —
Other/unknown 8 (6.1) —
Infarct-related artery
stenosis, %
(mean+SD)
96.4 + 11.6 —
Infarct-related artery
TIMI ﬂow, n (%)
0 84 (63.6) —
1 16 (12.1) —
2 14 (10.6) —
3 11 (8.3) —
Not available 7 (5.3)
Final results
Infarct-related artery
residual
stenosis, %
(mean+SD)
10.6 + 25 —
Infarct-related artery
TIMI ﬂow, n (%)
—
0 7 (5.3) —
1 2 (1.5) —
2 13 (9.8) —
3 103 (78) —
Not available 7 (5.3)
PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction.
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Table 1 Baseline clinical characteristics
Primary PCI
(n 5 132)
Fibrinolysis
(n 5 134)
Baseline characteristics
Age, years (mean+SD) 81.2 + 4.6 81 + 4.3
Male gender, n (%) 74 (56.1) 76 (56.7)
Weight, kg (mean+SD) 70.3 + 11 69 + 10.5
Height, cm (mean+SD) 162.5 + 7.8 161.8 + 8.4
Risk factors, n (%)
Hypertension 78 (59.1) 91 (67.9)
Dyslipidaemia 36 (27.3) 56 (41.8)
Diabetes mellitus 45 (34.1) 35 (26.1)
Treatment with insulin 14 (10.6) 12 (9)
Current smokers 20 (15.2) 15 (11.2)
Previous cardiovascular
disease, n (%)
Previous myocardial
infarction
10 (7.6) 12 (9)
Unstable angina 12 (9.1) 23 (17.2)
Chronic stable angina 18 (13.6) 14 (10.4)
Previous PCI 5 (3.8) 7 (5.2)
Previous CABG 1 (0.8) 2 (1.5)
Heart failure 1 (0.8) 2 (1.5)
Peripheral artery disease 12 (9.1) 14 (10.4)
Admission characteristics
Systolic blood pressure,
mmHg (mean+SD)
132.3 + 23.1 136.1 + 24.8
Heart rate, b.p.m.
(mean+SD)
73.4 + 18 75.5 + 17.9
Killip class, n (%)
1 108 (81.8) 113 (84.3)
2 20 (15.2) 15 (11.2)
3 4 (3) 4 (3)
ECG presentation, n (%)
Anterior location 64 (48.5) 56 (41.8)
Left bundle branch block 3 (2.3) 3 (2.2)
TIMI risk score
(mean+SD)
5.7 + 1.7 5.6 + 1.5
Creatinine, mg/dL
(mean+SD)
1.13 + 0.34 1.09 + 0.36
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting;
TIMI, thrombolysis in myocardial infarction.
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TRIANA pilot registry,
10 with the following assumptions: 21.7% inci-
dence of the primary endpoint in the ﬁbrinolysis group and 12.9% in
the pPCI group. At alpha-level 5% and beta-level 20%, with an
expected 1% loss to follow-up rate, the sample size needed to show
differences was calculated in 570 patients.
Pooled analysis
Additionally, we conducted a quantitative analysis combining our
results with those of previous reperfusion trials performed in older
patients by calculating ORs and 95% CIs for each trial. A x
2 analysis
was used to assess heterogeneity. Because the latter was not signiﬁ-
cant, a ﬁxed effects model was used. An overall OR with 95% CI
was calculated, with studies weighted according to the Mantel–Haens-
zel method using a Review Managerw 4.2.7 software.
Results
Since March 2005, 266 patients with STEMI were randomized, 132
to pPCI and 134 to ﬁbrinolysis. The study ﬂowchart is shown in
Figure 1. The study was interrupted due to slow recruitment in
December 2007. Baseline characteristics were well balanced
between groups except for dyslipidaemia (Table 1). Age ranged
from 75 to 94 years.
Table 2 shows the information related to reperfusion therapies.
Tenecteplase was administered in a median of 10 min after ran-
domization and achieved a clinically successful reperfusion in 74%
of patients. Rescue PCI was performed in 15% of cases. Among
patients who underwent pPCI, baseline thrombolysis in myocardial
infarction (TIMI) ﬂow 0–1 was present in 78% of the available
studies. A TIMI 3 ﬂow was achieved after the procedure in 82.4%
of the patients who underwent pPCI. Glycoprotein IIb/IIIa antagon-
ists were used during reperfusion in 65 patients (49.6%), coronary
stents in 111 (84%), and intra-aortic ballon pump in 6 (4.5%).
In-hospital management is shown in Table 3.M o r ep a t i e n t si nt h e
pPCIarm receivedclopidogrel,heparin,and nitroglycerine.Coronary
angiography was performed in 40% of the patients after ﬁbrinolysis,
15% on an urgent basis, and non-primary PCI was performed in 37%.
The primary endpoint (30-day death, re-infarction, or disabling
stroke) was achieved in 18.9% of the patients treated with pPCI
when compared with 25.4% of the patients treated with ﬁbrinolysis
(OR, 0.69; 95% CI 0.38–1.23). The incidence of each of the com-
ponents of the primary endpoint and other outcomes is shown in
Table 4. Although not statistically signiﬁcant, all-cause mortality,
re-infarction, and stroke were directionally lower with pPCI.
Importantly, there were only four strokes in the ﬁbrinolysis
group, all of them originally ischaemic. There were no signiﬁcant
...............................................................................................................................................................................
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Table 3 In-hospital management
Primary PCI (n 5 132) Fibrinolysis (n 5 134) P-value
Medical treatment, n (%)
Aspirin 127 (96.2) 130 (97) 0.73
Clopidogrel 121 (91.7) 84 (62.7) ,0.0001
Unfractionated heparin 117 (90.0) 122 (91.0) 0.77
Dose during reperfusion (UI, mean+SD) 5134 + 1672 3852 + 726 ,0.0001
Low-molecular-weight heparin 7 (5.4) 9 (6.7) 0.65
Intravenous nitroglycerine 66 (50) 91 (67.9) 0.004
Oral b-blockers 101 (76.5) 102 (76.1) 0.85
Angiotensin-converting enzyme inhibitor 108 (81.8) 115 (85.8) 0.44
Diuretics 66 (50) 60 (44.8) 0.36
Inotropic agents 26 (19.7) 22 (16.4) 0.47
Statins 118 (89.4) 117 (87.3) 0.46
Procedures, n (%)
Echocardiography 117 (88.6) 124 (92.5) 0.27
Pre-discharge LVEF 0.17
.50% 47 (35.6) 61 (45.5)
.40–50% 30 (22.7) 28 (20.9)
30–40% 27 (20.5) 14 (10.4)
,30% 15 (11.4) 12 (9)
Unknown 9 (6.8) 10 (7.5)
Non-invasive testing 6 (4.5) 26 (19.4) ,0.0001
Positive test 0 (0) 11 (42.3) ,0.0001
Coronary angiography 19 (14.4) 54 (40.3) ,0.0001
Non-primary PCI 16 (12.1) 49 (36.6) ,0.0001
Coronary artery bypass grafting 2 (1.5) 0 (0) 0.25
Hospital stay, days (median, 25th–75th percentiles) 9 (6–13) 9 (7–13) 0.78
PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction.
H. Bueno et al. 54differences in other complications such as major haemorrhage,
blood transfusion, or renal failure. Primary PCI greatly reduced
recurrent ischaemia needing urgent coronary angiography at 30
days. The outcomes for the composite endpoint and for mortality
at 1 year are shown in Figure 2.
The efﬁcacy of pPCI vs. ﬁbrinolysis on the primary endpoint
according to different pre-deﬁned subgroups is shown in
Figure 3. Only 23 patients received reperfusion within the ﬁrst
2 h from symptom onset, 18 with ﬁbrinolysis, and 5 with pPCI.
No deaths occurred in these patients at 30 days compared with
16.7% in those treated later (P ¼ 0.03). They also showed a
lower incidence of the primary endpoint (4.3 vs. 23.8%, P ¼
0.03), but the numerical difference in event rates in favour of
pPCI over ﬁbrinolysis remained unchanged.
The results of our study were pooled with those of the two pre-
vious randomized trials comparing ﬁbrinolysis and pPCI in older
..............................................................................................................................................................................
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Table 4 Thirty-day and one-year outcomes
Primary PCI
(n 5 132)
Fibrinolysis
(n 5 134)
OR (95%CI),
pPCI vs. lysis
P-value
30-day outcomes, n (%)
Primary endpoint (death, re-infarction, disabling stroke) 25 (18.9) 34 (25.4) 0.69 (0.38–1.23) 0.21
All-cause mortality 18 (13.6) 23 (17.2) 0.76 (0.39–1.49) 0.43
Cause of death, n (% of deaths) 0.36
Pump failure 4 (22) 5 (22)
Mechanical complication or EMD 5 (28) 11 (48)
Other 9 (50) 7 (30)
Re-infarction 7 (5.3) 11 (8.2) 0.63 (0.24–1.67) 0.34
,24 h 2 (1.5) 6 (4.5) 0.33 (0.07–1.66) 0.28
.24 h 5 (3.8) 5 (3.7) 1.02 (0.29–0.36) 0.98
Stroke 1 (0.8) 4 (3) 0.16 (0.02–1.37) 0.37
Ischaemic stroke 1 (0.8) 4 (3) 0.16 (0.02–1.37) 0.37
Haemorrhagic stroke 0 0
a
Disabling stroke 1 (0.8) 4 (3) 0.16 (0.02–1.37) 0.37
New heart failure 14 (10.6) 15 (11.2) 0.94 (0.43–2.04) 0.88
Shock 13 (9.8) 7 (5.2) 1.98 (0.77–5.14) 0.15
Recurrent ischaemia 1 (0.8) 13 (9.7) 0.07 (0.01–0.55) 0.001
Mechanical complications 4 (3.0) 10 (7.5) 0.49 (0.16–1.48) 0.17
Major haemorrhage 5 (3.8) 6 (4.5) 0.84 (0.25–2.82) 0.78
Transfusion 7 (5.3) 4 (3) 1.82 (0.52–6.37) 0.38
Major haemorrhage or transfusion 12 (9.1) 9 (6.7) 1.39 (0.56–3.41) 0.47
Acute renal failure 8 (6.1) 10 (7.5) 0.79 (0.30–2.08) 0.64
One-year outcomes (cumulative)
Death, re-infarction, or disabling stroke 36 (27.3) 43 (32.1) 0.79 (0.47–1.34) 0.39
All-cause mortality 28 (21.2) 31 (23.1) 0.90 (0.50–1.60) 0.71
Cardiac 18 (13.6) 23 (17.2)
Non-cardiac 5 (3.8) 7 (5.2)
Unknown 5 (3.8) 1 (0.7)
Re-infarction 11 (8.3) 14 (10.4) 0.78 (0.34–1.59) 0.56
Stroke 1 (0.8) 5 (3.8) 0.20 (0.02–1.71) 0.37
Heart failure 19 (14.4) 20 (14.9) 0.96 (0.49–1.89) 0.90
Recurrent ischaemia 1 (0.8) 16 (11.9) 0.06 (0.01–0.43) ,0.001
Major haemorrhage 8 (6.1) 7 (5.2) 1.17 (0.41–3.33) 0.77
Urgent rehospitalization
n (% of hospital survivors) 34 (29.3) 29 (26.1) 1.27 (0.72–2.24) 0.59
Cardiac 19 (16.5) 16 (14.4)
Non-cardiac 17 (14.8) 13 (11.7)
PCI, percutaneous coronary intervention; EMD, electromechanical dissociation.
aOne patient developed an ischaemic stroke after a coronary angiography on the seventh day of evolution, which converted to haemorrhagic stroke on the following day leading
to death.
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5–7 Differences in baseline characteristics, designs, and
results are shown in Appendix 3. The overall risk of death,
re-infarction, or disabling stroke was substantially lower for
patients allocated to pPCI compared with those treated with ﬁbri-
nolysis (14.9 vs. 21.5%; OR, 0.64; 95% CI 0.45–0.91; P ¼ 0.013).
The pooled rate of death showed a similar trend in favour of
pPCI, but the difference was not statistically signiﬁcant (Figure 4).
Discussion
We conducted a randomized trial comparing pPCI and ﬁbrinolysis
in a series of very old patients with STEMI. Unfortunately, the study
had to be prematurely interrupted due to the slow recruitment
rate and the impossibility to reach the target population.
However, the study results are meaningful and may be clinically
useful when combined with previous evidence.
Effects of reperfusion in the elderly
The use of ﬁbrinolysis for the treatment of STEMI in the elderly has
been controversial from the beginning. A ﬁrst meta-analysis found
that its effect on mortality was not superior to placebo in patients
.75 years old.
11 A later reassessment of the same data including
only properly selected patients indicated that the beneﬁt in the
oldest patients was actually greater than that for younger patients.
12
Finally, some observational studies suggested that ﬁbrinolysis could
be deleterious in very old patients with STEMI,
13,14 whereas only
patients treated with pPCI showed better 30-daysurvival compared
with those who did not receive reperfusion therapy.
15
To date, only two randomized studies have speciﬁcally
addressed the issue of pPCI vs. ﬁbrinolysis in the elderly. In the
Zwolle
5 study, the 46 patients allocated to pPCI showed a lower
2-year mortality rate compared with those treated with streptoki-
nase (15 vs. 32%, P ¼ 0.04). The larger, yet unpublished, Senior
PAMI trial,
6,7 which randomized 481 patients .70 years old
failed to document differences between pPCI and ﬁbrinolysis in
the primary outcome (30-day mortality or stroke) or in mortality
(Appendix 3). Moreover, a post-hoc analysis showed a non-
signiﬁcant trend towards a higher mortality rate in patients .80
years old allocated to pPCI (19 vs. 16%).
7 With this in mind, the
present study was undertaken to further deﬁne the role of these
strategies in a contemporary clinical setting with updated antith-
rombotic ancillary therapies.
Clinical outcomes
In this trial, pPCI was associated with a non-signiﬁcant reduction in
the composite endpoint of death, recurrent infarction, and dis-
abling stroke after 30 days, with a similar direction in the estimates
of the effect on each of the three individual components of the
Figure 2 One-year Kaplan–Meier survival curves free of death,
re-infarction, or disabling stroke (primary endpoint) (A) or all-
cause mortality (B). PCI, percutaneous coronary intervention.
Figure 3 Odds ratio for efﬁcacy of primary angioplasty com-
pared with ﬁbrinolysis according to different pre-deﬁned sub-
groups. PCI, percutaneous coronary intervention.
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substantial reduction in recurrent ischaemia, which remained sig-
niﬁcant throughout the follow-up. Although generally regarded
as a soft endpoint, recurrent ischaemia was precisely deﬁned in
the present study as that requiring catheterization, and was exter-
nally adjudicated. It is remarkable that the small proportion of
patients who underwent reperfusion within the ﬁrst 2 h from
symptom onset achieved excellent clinical results.
The cost of ﬁbrinolysis in terms of bleeding was low. Only four
strokes occurred in this treatment arm and none of them were
originally haemorrhagic. In addition, no differences in major bleed-
ing or transfusion need between the two treatments could be
demonstrated. Careful dosing and monitoring of antithrombotic
and anticoagulant medications, including TNK, aspirin, clopidogrel,
and heparin, probably accounted for it.
In keeping with contemporary practice, use of stents in this trial
was higher (84%) than in representative studies (51% in the Zwolle
series
5). In spite of that, TIMI 3 grade ﬂow in TRIANA was compara-
tively lower (83% of those attempted vs. 90%). These differences
might be due to either a more globally representative outcome in
the present study, to the fact that even in angiographic core labora-
tories determinations of TIMI ﬂow are often discrepant, or both.
Overall perspective after TRIANA
The observations using data from all prospective randomized trials
performed in very old patients with STEMI provide good evidence
that pPCI improves outcomes in this setting. Although the need for
a large community-based multicentre conﬁrmation trial still
remains desirable, successful enrollment for such a study
appears—as in previous attempts—very unlikely since most clini-
cians are strongly convinced of the superiority of pPCI.
4
Study limitations
The study was halted prematurely before the planned enrollment
could be met. This decision was taken by the executive committee
owing to slow recruitment. As a result, the study is underpowered
to properly test the primary endpoint. We used restrictive entry cri-
teria,particularlyconcerninghighbloodpressureand priorhistoryof
stroke.Thistranslatedintoareductioninthenumberofpotentialcan-
didates and a more selected population, but major concern about
safety, particularly increased bleeding risk, dictated this policy. Also,
the population enroled was quite ﬁt, with a low prevalence of heart
failure in the past and on admission, which may reduce the extrapol-
ability of the results to broader populations. The present study was
unblinded as comparisons between angioplasty and pharmacologic
reperfusion therapy are by nature, and thus, suboptimal. However,
patienttreatmentswereblindedtotheeventadjudicationcommittee.
Better outcomes could have been obtained in both arms if faster
reperfusion had been achieved, and current recommended co-
adjuvant therapies, such as abciximab or higher clopidogrel loading
doses had been more frequently used in patients undergoing pPCI.
However, that was not standard care in 2004 when the study was
designed. Finally, rescue PCI, a procedure that could inﬂuence
outcome, was only performed in 15% of the patients receiving ﬁbri-
nolytic treatment, a rate probably low for today standards in
Figure 4 Odd-ratios for mortality and the combined endpoint in the three randomized trials comparing primary percutaneous coronary
intervention and ﬁbrinolysis performed in very old patients with ST-segment elevation myocardial infarction. PCI, percutaneous coronary
intervention.
Primary PCI vs. ﬁbrinolysis in the elderly 57younger people. As a reference, although the number of rescue PCIs
performed inthe Zwolletrial
5 and inSeniorPAMI
7 was not stated, in
thelatter37%ofpatientsunderwentin-hospitalrepeatedcatheteriza-
tion, a proportion comparable with that in TRIANA.
Conclusions
Our results complement previous work suggesting that pPCI may
offer clinical advantage over ﬁbrinolytic therapy as manifested by
the trends towards improvements in the combined endpoint of
death, re-infarction, and stroke at 30 days in the oldest patients.
In addition, we have observed that mechanical reperfusion
encompasses a signiﬁcant reduction in adjudicated recurrent
ischaemia. Thus, pPCI seems to be the reperfusion strategy of
choice also in very old patients presenting with STEMI. Since
state-of-the-art ﬁbrinolysis appears to be safe, it may be
considered a valuable alternative when pPCI is not available,
particularly when initiated early.
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Appendix 1
Study organization
Steering Committee:H e ´ctor Bueno (chair), Rosana
Herna ´ndez-Antolı ´n (co-chair), Joaquı ´n J. Alonso, Amadeo Betriu,
Angel Cequier, Eulogio J. Garcı ´a, Magda Heras, Jose ´
L. Lo ´pez-Sendo ´n, Carlos Macaya.
Data Safety and Monitoring Board: Jose ´ Azpitarte (chair).
Adjudication Committee: Gine ´s Sanz (chair), Angel Cha-
morro, Ramo ´nL o ´pez-Palop, Alex Sionis, Fernando Aro ´s.
Participating centres, number of patients enroled,
and principal investigators:
† Hospital General Universitario Gregorio Maran ˜o ´n, Madrid (30):
Eulogio Garcı ´a-Ferna ´ndez, Rafael Rubio;
† Hospital12deOctubre,Madrid(29):FelipeHerna ´ndez,JuanCarlos
Tasco ´n;
† Hospital Virgen de la Salud, Toledo (23): Jose ´ Moreu;
† Hospital Clı ´nic de Barcelona (20): Amadeu Betriu, Magda Heras;
† Hospital Clı ´nico San Carlos, Madrid (19): Rosana
Herna ´ndez-Antolı ´n, Antonio Ferna ´ndez-Ortiz;
† Hospital Central de Asturias, Oviedo (19): Ce ´sar Morı ´s, Ignacio
Sa ´nchez de Posada;
† HospitalBellvitge,Barcelona(18):A ´ngelCequier,EnriqueEsplugas;
† Hospital Universitario Virgen de las Nieves, Granada (17): Rafael
Melgares;
† Hospital Universitario de Canarias, Las Palmas (15): Francisco
Bosa, Martı ´n Jesu ´s Garcı ´a-Gonza ´lez;
† Hospital de Navarra, Pamplona (15): Roma ´n Leza ´un, Jose ´
Ramo ´n Carmona;
† Hospital Juan Canalejo, A Corun ˜a (14): Jose ´ Manuel Va ´zquez,
Alfonso Castro-Beiras;
† Hospital Santa Creu i Sant Pau, Barcelona (8): Joan Garcı ´a Picart,
Jose ´ Domı ´nguez de Rozas;
† Hospital Juan Ramo ´n Jime ´nez, Huelva (8): Jose ´ Dı ´az Ferna ´ndez;
† Complejo Hospitalario de Leo ´n (4): Felipe Ferna ´ndez Va ´zquez,
Norberto Alonso;
† Hospital Marque ´s de Valdecilla, Santander (4): Jose ´ Javier Zueco,
Jose ´ Marı ´a San Jose ´;
† Hospital Clı ´nico Universitario de Valladolid (4): Alberto San
Roma ´n, Carolina Herna ´ndez;
† Hospital Virgen de la Victoria, Ma ´laga (4): Jose ´ Marı ´a Herna ´ndez
Garcı ´a, A ´ngel Garcı ´a Alca ´ntara;
† Hospital Universitario Son Dureta, Palma de Mallorca (3):
Armando Bethencourt, Miquel Fiol;
† HospitalCruces,Bilbao(3):XabierMancisidor,XabierMancisidor;
† Hospital Virgen de la Macarena, Sevilla (3): Rafael Ruiz, Rafael
Hidalgo;
† Hospital Universitario La Paz, Madrid (3); Nicola ´s Sobrino,
Isidoro Gonza ´lez Maqueda;
† HospitalTxagorritxu,Vitoria(2):AlfonsoTorres,FernandoAro ´s;
† Hospital Universitario de Santiago de Compostela (1): Antonio
Amaro, Michel Jaquet.
Appendix 2
Study operational deﬁnitions
All events were evaluated by an ad hoc independent committee of
experts, including three cardiologists and one neurologist, who
were blinded to the treatment received by the patient. The follow-
ing operative deﬁnitions were used for outcome adjudication.
Death: death of any cause that occurred since randomization
until the end of follow-up. Information was obtained from clinical
records or any other reliable source. The causes of death at 30
days were classiﬁed in three groups: shock or heart (pump)
failure, mechanical complications or electromechanical dissociation,
and other causes (including bleeding).
Re-infarction: it was deﬁned according to the time of occurrence.
Within ﬁrst 24 h after randomization, re-infarction was deﬁned as
the recurrence of symptoms of myocardial ischaemia with
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ST-segment elevation .0.1 mV in at least two or more adjacent
leads for at least 30 min. After the ﬁrst 24 h, troponin re-elevation
or increase of creatine kinase-MB levels or appearance of new
Q-waves in two or more leads were also requested.
Disabling stroke: presence of new permanent focal or generalized
neurologic symptoms affecting the normal life of a patient, associ-
ated to abnormal ﬁndings (ischaemic or haemorrhagic lesions) in a
computed tomography or magnetic resonance imaging.
Heart failure: presence of new symptoms or signs suggesting
heart failure (dyspnoea, orthopnoea, third sound, or rales on pul-
monary auscultation associated with signs of pulmonary congestion
in a chest X-ray) after the ﬁrst 24 h.
Recurrent ischaemia: cardiac catheterization indicated for angina
with ST-segment shift or T-wave inversion, provided that
re-infarction criteria were not fulﬁlled.
Shock: presence of persistent hypotension (systolic blood
pressure ,90 mmHg with no response to volume load) associated
with signs of low cardiac output, regardless of its cause.
Mechanical complication: clinical evidence of rupture of the free
ventricular wall or the interventricular septum, or severe mitral
regurgitation secondary to total or partial rupture of a papillary
muscle, conﬁrmed by any diagnostic technique.
Major bleeding: cerebral haemorrhage or any other bleeding
associated with a haemoglobin drop ≥5 g/dL, or an absolute hae-
matocrit drop ≥15%.
The time from admission to the initiation of therapy was calcu-
lated as the time to the start of the lytic infusion or the ﬁrst balloon
inﬂation.
Appendix 3
Randomized controlled trials
comparing primary percutaneous
intervention vs. ﬁbrinolysis in
older patients with ST-segment
elevation myocardial infarction
Table A1 Comparison of trials designs and baseline characteristics
de Boer Senior PAMI TRIANA
Age limit (years) .75 ≥70 ≥75
Time limit ,6 h (6–24 h, if continuing ischaemia) ,12 h ,6h
Study years 1996–1999 2000–2005 2005–2007
Patients enroled, n (lytics/pPCI) 87 (41/46) 481 (229/252) 266 (134/132)
Primary endpoint (all incidence
at 30 days)
Death, re-infarction, or stroke Death or disabling stroke Death, re-infarction, or disabling
stroke
Participant hospitals Single centre (Zwolle, the Netherland) Multicentre international 23 hospitals in Spain
Lytic agent SK 100% SK 38%; TNK/tPA/rPA 62% TNK 100%
Antiplatelet therapy lysis arm Aspirin i.v. 450 mg N/A Aspirin 300 mg, clopidogrel 75 mg
q.d. × 28 days
a
Antiplatelet therapy pPCI arm Aspirin i.v. 450 mg ticlopidine 250 mg
b.i.d. × 2 weeks
a
N/A Aspirin 300 mg, clopidogrel
300 mg + 75 mg q.d.
Anticoagulation UFH (for aPTT 2–3) N/A UFH 60 units/kg (maximum 4000 U)
Glycoprotein IIb/IIIa inhibitors
for pPCI
Not used N/A Abciximab (49.6%)
Stents during pPCI 51% N/A 84%
Door to reperfusion, minutes
(mean+SD)
Lytics: 31+15; pPCI: 59+19 Lytics: 62; pPCI: 82 Lytics: 59+40; pPCI: 107+47
Age, years median, (P25–P75);
range
Lytics: 81 (78–84); 75 (N/A); pPCI: 80
(77–84); 75 (N/A)
Lytics: 77 (N/A); 70–101; pPCI:
78 (N/A); 70–99
Lytics: 80 (78–84); 75–94; pPCI: 80
(78–84); 75–94
Male gender (%) Lytics: 61; pPCI: 48 Lytics: 60; pPCI: 58 Lytics: 56; pPCI: 57
Diabetes (%) Lytics: 17; pPCI: 24 Lytics: 20; pPCI: 25 Lytics: 34; pPCI: 26
Anterior location (%) 50 45 45
Killip .II (%) Lytics: 10; pPCI: 13 N/A Lytics: 3; pPCI: 3
N/A, not available; pPCI, primary percutaneous coronary intervention.
aSince December 2006.
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Table A2 Comparison of trials results
de Boer Senior PAMI TRIANA
Endpoints
Primary endpoint
a (%) Lytics 29 13 25.4
pPCI 9 11.3 18.9
Mortality (%) Lytics 22 13 17.2
pPCI 7 10 13.6
Re-infarction (%) Lytics 15 5.4 8.2
pPCI 2 1.6 5.3
Stroke (%) Lytics 7 N/A 3
pPCI 2 N/A 0.8
Disabling stroke (%) Lytics N/A 2.2 3.0
pPCI N/A 0.8 0.8
Major bleeding (%) Lytics 7 N/A 4.5
pPCI 11
b N/A 3.8
Risk/odds ratios lysis vs. pPCI
Primary endpoint RR 4.3 (1.2–20) N/A OR 1.46 (0.81–2.61)
Mortality RR 4.0 (0.9–24.6) N/A OR 1.31 (0.67–2.56)
Re-infarction N/A N/A OR 1.60 (0.60–4.25)
Disabling stroke N/A N/A OR 4.03 (0.44–36.5)
aSee deﬁnition in Table 1; pPCI, primary percutaneous coronary intervention.
bNon-cerebral bleeding.
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